The COVID-19 pandemic and ANCA-associated vasculitis–reports from the EUVAS meeting and EUVAS education forum
A Kronbichler, D Geetha, RM Smith, AC Egan… - Autoimmunity …, 2021 - Elsevier
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic influenced the management
of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. A paucity …
of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. A paucity …
New-onset systemic vasculitis following SARS-CoV-2 infection and vaccination: the trigger, phenotype, and outcome
The global health crisis caused by the COVID-19 pandemic overwhelmed the capacity of
healthcare systems to cope with the rapidly spreading infection and its associated …
healthcare systems to cope with the rapidly spreading infection and its associated …
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a …
Background Patients with primary systemic vasculitis or polymyalgia rheumatica might be at
a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ …
a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ …
Two years with COVID-19: New-and old-challenges for health communication research
RL Street Jr, A Finset - Patient Education and Counseling, 2022 - Elsevier
In mid-2020 we ran an editorial in PEC, Effective health communication–a key factor in
fighting the COVID-19 pandemic, that identified specific areas where more effective health …
fighting the COVID-19 pandemic, that identified specific areas where more effective health …
[HTML][HTML] A rare case of SARS-CoV-2-induced microscopic polyangiitis
N Allena, J Patel, G Nader, M Patel, B Medvedovsky - Cureus, 2021 - ncbi.nlm.nih.gov
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection triggers elevated
levels of circulating cytokines and immune-cell hyperactivation, called a cytokine storm …
levels of circulating cytokines and immune-cell hyperactivation, called a cytokine storm …
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
One year into the coronavirus disease 2019 (COVID-19) epidemic, data regarding a more
detailed risk profile and treatment aspects of patients with immune-mediated kidney …
detailed risk profile and treatment aspects of patients with immune-mediated kidney …
Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis
L Quartuccio, E Treppo, M Binutti, G Del Frate… - …, 2021 - academic.oup.com
1 Tepasse PR, Hafezi W, Lutz M et al. Persisting SARS-CoV-2 viraemia after rituximab
therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 2020; …
therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 2020; …
Timing of COVID-19 vaccine in the setting of anti-CD20 therapy: a primer for nephrologists
The corona virus disease 2019 (COVID-19) pandemic has continued to pose challenges to
health care systems worldwide. This includes care of patients requiring immunosuppression …
health care systems worldwide. This includes care of patients requiring immunosuppression …
De Novo and Relapsing Glomerulonephritis following SARS‐CoV‐2 mRNA Vaccination in Microscopic Polyangiitis
T Davidovic, J Schimpf… - Case Reports in …, 2021 - Wiley Online Library
Vaccination against SARS‐CoV‐2 is the most important advance in the fight against the
ongoing coronavirus pandemic. Recent case reports show that the SARS‐CoV‐2 vaccines …
ongoing coronavirus pandemic. Recent case reports show that the SARS‐CoV‐2 vaccines …
Risks and treatment related aspects of COVID-19 infection in patients with ANCA-associated vasculitis
A Antovic, A Bruchfeld, J Ekland… - Scandinavian Journal …, 2023 - Taylor & Francis
Objective Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
(AAV) require immunosuppressive therapy for disease control and relapse prevention and …
(AAV) require immunosuppressive therapy for disease control and relapse prevention and …